Satellos Bioscience Inc. (Satellos), a biotech company developing new small-molecule therapeutic approaches to improve the treatment of muscle diseases, appointed Wildon Farwell, M.D., MPH, as chief medical officer (CMO).

Farwell succeeds Jordan Dubow, MD, who has served as Satellos’ part-time CMO since January 2024. Dubow will continue to serve as a consultant to Satellos and chair of its Clinical Advisory Board.

Farwell joins Satellos from Dyne Therapeutics, where he most recently served as CMO and medical advisor.

At Dyne, Farwell built the development organization, led the protocol development and regulatory submissions for their Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs, oversaw the conduct of multiple potentially registrational clinical studies, and contributed to several successful capital raises. 

Before Dyne, he spent a decade at Biogen in increasing leadership roles, including vice president of Late-Stage Clinical Development and global medical head of Neuromuscular Diseases. During his time at Biogen, Farwell led the development and lifecycle management of Spinraza, the first approved treatment for spinal muscular atrophy. He also initiated late-stage development of Qalsody, an investigational therapy for amyotrophic lateral sclerosis. 

Farwell also led biomarker development and pharmacovigilance for therapies across multiple indications. Before moving into industry, Farwell served as an assistant professor of medicine at Harvard Medical School and was a physician at Brigham and Women’s Hospital and the VA Boston Healthcare System.

Frank Gleeson, Satellos co-founder and CEO, said, “[Dr. Farwell] brings deep expertise in global clinical development — particularly in neuromuscular and rare diseases — and a strong track record of successfully advancing novel therapies through regulatory approval. His experience will be invaluable as we move SAT-3247 into a global, randomized, placebo-controlled Phase 2 clinical trial in children living with DMD, with the goal of delivering a transformative treatment.”